Abiopharma

News list

MILESTONE PHARMACEUTICALS INC. (MIST)

SEC News
Sept. 03, 2026, 20:03 UTC

(70% Positive) MILESTONE PHARMACEUTICALS INC. (MIST) Announces Enrollment Update for spray Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text

News bot Sept. 3, 2026, 8:05 p.m.

📋 MILESTONE PHARMACEUTICALS INC. (MIST) - Clinical Trial Update

Filing Date: 2026-09-03

Accepted: 2026-09-03 16:03:58

Event Type: Clinical Trial Update

Event Details:

MILESTONE PHARMACEUTICALS INC. (MIST) Announces Clinical Trial Update MILESTONE PHARMACEUTICALS INC. (MIST) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: spray, Spray
Diseases/Conditions: PSVT in China, Greater China
Collaboration: Milestone Pharmaceuticals MONTREAL

🔬 Clinical Development Pipeline (MILESTONE PHARMACEUTICALS INC.):

Product	Type	Development Stage	Therapeutic Area	Source
Etripamil	Other	Phase PHASE3	Atrial Fibrillation	ClinicalTrials.gov
Placebo	Other	Phase PHASE3	Atrial Fibrillation	ClinicalTrials.gov
Etripamil NS	Other	Phase PHASE2	Paroxysmal Supraventricular Tachycardia	ClinicalTrials.gov
Aptar Pharma Nasal Spray Bidose System	Other	Phase PHASE3	Paroxysmal Supraventricular Tachycardia	ClinicalTrials.gov
Etripamil NS 70 mg	Other	Phase PHASE3	Paroxysmal Supraventricular Tachycardia	ClinicalTrials.gov
MultiZYTE	Other	Approved	Chronic Lower Back Pain (CLBP)	ClinicalTrials.gov
Corticosteroid Injection	Other	Approved	Fasciitis, Plantar	ClinicalTrials.gov
ReNu Injection	Other	Approved	Fasciitis, Plantar	ClinicalTrials.gov
Etripamil Nasal Spray 70mg	Other	Phase PHASE1	Healthy Chinese Subjects	ClinicalTrials.gov
Etripamil Test Dose	Other	Phase PHASE3	Paroxysmal Supraventricular Tachycardia	ClinicalTrials.gov

💼 Business Developments:

Partnership
Acquisition: Not available
Licensing
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: MILESTONE PHARMACEUTICALS INC.
Ticker Symbol: MIST